Larvol Delta - Argo-Biopharmaceuticalannounced-that-the-rst-patient-has-been-dosed-in-a-global-Phase-2b-clinical-trial-sponsored-by-Novartis-evaluating-DII235-also-known-as-BW20829-in-adults-with-elevated-Lipoprotein-a-Lpa-and-Atherosclerotic-Cardiovascular-Disease-ASCVD

BW-20829 - Argo Biopharma, Novartis

https://www.prnewswire.com/news-releases/argo-biopharma-announces-first-patient-dosed-in-phase-2b-trial-of-sirna-therapeutic-bw-20829-in-patients-with-elevated-lpa-302669577.html

Jan 25, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next